ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853
- Potential new therapeutic for ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors which over-express folate receptor 1 (FOLR1).
- Achievement of active IND for IMGN853 closely follows start of patient dosing with IMGN529 and initiation of Phase II testing with IMGN901.
- IMGN853 Phase I evaluation expected to begin in mid-2012.
Recently the Company announced the start of Phase II testing with its IMGN901 compound in small-cell lung cancer and — earlier today — it announced the start of Phase I testing with its IMGN529 compound in non-Hodgkin's lymphoma. All three product candidates utilize the Company's Targeted Antibody Payload (TAP) technology with ImmunoGen antibodies and are wholly owned by the Company.
"Our progress with IMGN901, IMGN529 and now IMGN853 speaks to our
commitment to build and effectively advance a product pipeline of
significant anticancer therapeutics," commented
About IMGN853
ImmunoGen created IMGN853 for the treatment of ovarian cancer, NSCLC, and other epithelial malignancies that over-express FOLR1. The compound comprises the Company's highly potent cancer-cell-killing agent, DM4, attached to its M9346A FOLR1-targeting antibody using one of the novel linkers ImmunoGen designed to counter multi-drug resistance. Many cancers develop multi-drug resistance with continued treatment, making the tumors increasingly difficult to kill.
About
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN853, IMGN529 and IMGN901, including risks related to
preclinical and clinical studies, their timings and results. A review of
these risks can be found in ImmunoGen's Annual Report on Form 10-K for
the fiscal year ended
For Investors:
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Source:
News Provided by Acquire Media